Management of Pediatric Severe Traumatic Brain Injury

Publication Date: March 1, 2019
Last Updated: March 14, 2022

Recommendations

MONITORING

To Improve Overall Outcomes

Use of intracranial pressure (ICP) monitoring is suggested.

(Level III, C)
317039

Advanced Neuromonitoring

To Improve Overall Outcome

If brain tissue oxygenation (Pbro2) monitoring is used, maintaining a level greater than 10 mm Hg is suggested.

(Level III, C)
There was insufficient evidence to support a recommendation for the use of a monitor of Pbro2 to improve outcomes.
317039

THRESHOLDS

Thresholds for Treatment of Intracranial Hypertension

To Improve Overall Outcomes

Treatment of ICP targeting a threshold of less than 20 mm Hg is suggested.

(Level III, C)
317039

Thresholds for cerebral perfusion pressure (CPP)

To Improve Overall Outcomes

Treatment to maintain a CPP at a minimum of 40 mm Hg is suggested.

(Level III, C)
317039

A CPP target between 40 and 50 mm Hg is suggested to ensure that the minimum value of 40 mm Hg is not breached. There may be age-specific thresholds with infants at the lower end and adolescents at or above the upper end of this range.

(Level III, C)
317039

TREATMENTS

Hyperosmolar Therapy

For ICP Control

Bolus hypertonic saline (HTS) (3%) is recommended in patients with intracranial hypertension. Recommended effective doses for acute use range between 2 and 5 mL/kg over 10–20 minutes.

(Level II, C)
317039
For ICP Control

Continuous infusion HTS is suggested in patients with intracranial hypertension. Suggested effective doses as a continuous infusion of 3% saline range between 0.1 and 1.0 mL/kg of body weight per hour, administered on a sliding scale. The minimum dose needed to maintain ICP less than 20 mm Hg is suggested.

(Level III, C)
317039

Bolus of 23.4% HTS is suggested for refractory ICP. The suggested dose is 0.5 mL/kg with a maximum of 30 mL.

(Level III, C)
317039
Safety Recommendation (applies to all recommendations for this topic).

In the context of multiple ICP-related therapies, avoiding sustained (>72 hr) serum sodium greater than 170 mEq/L is suggested to avoid complications of thrombocytopenia and anemia, whereas avoiding a sustained serum sodium greater than 160 mEq/L is suggested to avoid the complication of deep vein thrombosis (DVT).

Note. Although mannitol is commonly used in the management of raised ICP in pediatric TBI, no studies meeting inclusion criteria were identified for use as evidence for this topic.

Analgesics, Sedatives, and NMB

For ICP Control

With use of multiple ICP-related therapies, as well as appropriate use of analgesia and sedation in routine ICU care, avoiding bolus administration of midazolam and/or fentanyl during ICP crises is suggested due to risks of cerebral hypoperfusion.

(Level III, C)
Note 1. In the absence of outcome data, the specific indications, choice, and dosing of analgesics, sedatives, and neuromuscular blocking agents should be left to the treating physician.
Note 2. Based on guidance from the U.S. Food and Drug Administration, prolonged continuous infusion of propofol for either sedation or the management of refractory intracranial hypertension is not recommended.
317039

Cerebrospinal Fluid (CSF) Drainage

For ICP Control

CSF drainage through an EVD is suggested to manage increased ICP.

(Level III, C)
317039

Seizure Prophylaxis

For Seizure Prevention (Clinical and Subclinical)

Prophylactic treatment is suggested to reduce the occurrence of early (within 7 d) PTSs.

(Level III, C)
Note. At the present time, there is insufficient evidence to recommend levetiracetam over phenytoin based on either efficacy in preventing early PTS (EPTS) or toxicity.
317039

Ventilation Therapies

To Improve Overall Outcomes

Prophylactic severe hyperventilation to a Paco2 less than 30 mm Hg in the initial 48 hours after injury is not suggested.

(Level III, C)
317039

If hyperventilation is used in the management of refractory intracranial hypertension, advanced neuromonitoring for evaluation of cerebral ischemia is suggested.

(Level III, C)
317039

Temperature Control/Hypothermia

To Improve Overall Outcomes

Prophylactic moderate (32–33°C) hypothermia is not recommended over normothermia to improve overall outcomes.

(Level II, B)
317039
For ICP Control

Moderate (32–33°C) hypothermia is suggested for ICP control.

(Level III, B)
317039
Safety Recommendation 1. If hypothermia is used and rewarming is initiated, it should be carried out at a rate of 0.5–1.0°C every 12–24 hours or slower to avoid complications.
Safety Recommendation 2. If phenytoin is used during hypothermia, monitoring and dosing adjusted to minimize toxicity, especially during the rewarming period, are suggested.

BARBITURATES

For ICP Control

High-dose barbiturate therapy is suggested in hemodynamically stable patients with refractory intracranial hypertension despite maximal medical and surgical management.

(Level III, C)
317039

Safety Recommendation. When high-dose barbiturate therapy is used to treat refractory intracranial hypertension, continuous arterial blood pressure monitoring and cardiovascular support to maintain adequate CPP are required because cardiorespiratory instability is common among patients treated with barbiturate coma.

Decompressive Craniectomy

For ICP Control

Decompressive craniectomy (DC) is suggested to treat neurologic deterioration, herniation, or intracranial hypertension refractory to medical management (MM).

(Level III, C)
317039

Nutrition

To Improve Overall Outcomes

Use of an immune-modulating diet is not recommended.

(Level II, C)
317039
To Improve Overall Outcomes

Initiation of early enteral nutritional support (within 72 hr from injury) is suggested to decrease mortality and improve outcomes.

(Level III, C)
317039

Corticosteroids

To Improve Overall Outcomes

The use of corticosteroids is not suggested to improve outcome or reduce ICP.

(Level III, C)

Note: This recommendation is not intended to circumvent use of replacement corticosteroids for patients needing chronic steroid replacement therapy, those with adrenal suppression, and those with injury to the hypothalamic-pituitary steroid axis.

317039

Recommendation Grading

Overview

Title

Management of Pediatric Severe Traumatic Brain Injury

Authoring Organization

Brain Trauma Foundation

Publication Month/Year

March 1, 2019

Last Updated Month/Year

June 13, 2023

Supplemental Implementation Tools

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Inclusion Criteria

Female, Male, Adolescent, Child, Infant

Health Care Settings

Emergency care, Operating and recovery room, Outpatient

Intended Users

Paramedic emt, nurse, nurse practitioner, physician, physician assistant

Scope

Management, Treatment

Diseases/Conditions (MeSH)

D000070642 - Brain Injuries, Traumatic

Keywords

critical care, concussion, traumatic brain injury

Source Citation

Kochanek, Patrick M. MD, MCCM1; Tasker, Robert C. MA, MD, FRCP2; Carney, Nancy PhD3; Totten, Annette M. PhD4; Adelson, P. David MD, FACS, FAAP, FAANS5; Selden, Nathan R. MD, PhD, FACS, FAAP6; Davis-O’Reilly, Cynthia BS7; Hart, Erica L. MST8; Bell, Michael J. MD9; Bratton, Susan L. MD, MPH, FAAP10; Grant, Gerald A. MD11; Kissoon, Niranjan MD, FRCP(C), FAAP, MCCM, FACPE12; Reuter-Rice, Karin E. PhD, CPNP-AC, FCCM, FAAN13; Vavilala, Monica S. MD14; Wainwright, Mark S. MD, PhD15 Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Pediatric Critical Care Medicine: March 2019 - Volume 20 - Issue 3S - p S1-S82 doi: 10.1097/PCC.0000000000001735
 

Supplemental Methodology Resources

Evidence Tables, Methodology Supplement

Methodology

Number of Source Documents
235
Literature Search Start Date
May 1, 2015
Literature Search End Date
June 1, 2017